Monday, 20 Jan 2020

You are here

Early Predictive Factors for Scleroderma Renal Crisis

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients. 

Researchers from Reed National Military Medical Center studied a systemic sclerosis (SSc) cohort seen between 2005 and 2016, specifically looking at 31 cases of newly diagnosed SSc cases who developed SRC after SSc diagnosis (compared to 322 without SRC).

The following findings at SSc diagnosis were predictive of future SRC:

  • proteinuria (p < 0.001; OR 183, 95% CI 19.1–1750),
  • anemia (p = 0.001; OR 9.9, 95% CI 2.7–36.2),
  • hypertension (p < 0.001; OR 13.1, 95% CI 4.7–36.6),
  • chronic kidney disease (p = 0.008; OR 20.7, 95% CI 2.2–190.7),
  • elevated erythrocyte sedimentation rate (p < 0.001; OR 14.3, 95% CI 4.8–43.0),
  • thrombocytopenia (p = 0.03; OR 7.0, 95% CI 1.2–42.7),
  • hypothyroidism (p = 0.01; OR 2.8, 95% CI 1.2–6.7),
  • anti-Ro antibody seropositivity (p = 0.003; OR 3.9, 95% CI 1.6–9.8), and
  • anti-RNA polymerase III antibodies (p = 0.02; OR 4.1, 95% CI 1.2–13.8).

Individually the predictive value for SRC was low, but finding any three or more of these present at diagnosis was sensitive (77%) and specific (97%) for future SRC. No SSc without SRC disease controls had ≥ 4 risk factors.

These profiles add to the current list and should be considered in new SSc patients as they may benefit from close observation of blood pressure, proteinuria, and other signs of renal crisis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

Best of 2019 - New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.